Abstracts Archive - Page 15 of 2607 - ACR Meeting Abstracts

Abstract Number: 0183 • ACR Convergence 2025
Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations
Alfredo Madrid¹, Diego Benavent², Chamaida Plasencia-Rodríguez³, Zulema Rosales-Rosado⁴, Beatriz Merino-Barbancho⁵ and DALIFER FREITES⁶, ¹Roche, Global Data Science and Analytics, Madrid, Spain., Madrid, Madrid, Spain, ²Hospital Universitari de Bellvitge, Madrid, Spain, ³Hospital Universitario La Paz, MADRID, Spain, ⁴Grupo de Patología Musculoesquelética. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, Madrid, Madrid, Spain, ⁵Escuela Técnica Superior de Ingenieros de Telecomunicación. Universidad Politécnica de Madrid. Avenida Complutense, Madrid, Spain, Madrid, Madrid, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain
Background/Purpose: Timely access to current rheumatology guidelines at the point of care presents a significant challenge. Large Language Models (LLMs) offer potential solutions, but their…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 2281 • ACR Convergence 2025
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Louis Bessette¹, Andrew Chow², Raman Rai³, Hugues Allard-Chamard⁴, Pauline Boulos⁵, Guylaine Roy⁶ and Dalinda Liazoghli⁶, ¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ²Credit Valley Rheumatology, Mississauga, McMaster University, Hamilton, University of Toronto, Toronto, ON, Canada, ³Drs. Rai & Sekhon Medicine Professional Corporation, Brampton, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶AbbVie Corporation, Saint-Laurent, QC, Canada
Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)-inhibitor proven effective and well-tolerated in patients with rheumatoid arthritis (RA) in 6 randomized clinical trials.…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 0132 • ACR Convergence 2025
Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
Fanshu Li, Ranran Yao, Fanlei Hu, Liling Xu and Chun Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…
Abstract Number: 0051 • ACR Convergence 2025
Spp1+ Macrophages Are Specifically Enriched in Arthritic Joints and Associated with Abnormal Bone Metabolism in Collagen-Induced Arthritis Mice
Chenjia He, Xuyang Xia, Heng Xu, Geng Yin and Qibing Xie, West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Synovial fluid (SF) of RA patients contains unique SPP1+ macrophages that drive pathogenesis by activating fibroblast-like synoviocytes (FLS). Single-cell RNA sequencing (scRNA-seq) data from…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 0103 • ACR Convergence 2025
Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
Félicie Costantino¹, roula Said-Nahal², Hendrick Mambu Mambueni³, Anne Boland⁴, Jean-François Deleuze⁴, Matthew Brown⁵, Henri-Jean Garchon³ and Maxime Breban⁶, ¹Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, ²Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Boulogne-Billancourt, France, ³Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Montigny le Bretonneux, France, ⁴Centre National de Recherche en Génomique Humaine (CNRGH), Centre National de Recherche en Génomique Humaine (CNRGH), Université Paris-Saclay, CEA, Evry, France, ⁵Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ⁶CHU Ambroise-Paré, Boulogne-Billancourt, France
Background/Purpose: Spondyloarthritis (SpA) exhibits strong familial aggregation, with close relatives of patients having a significantly higher risk of developing the disease. This pattern might be…
Abstract Number: 0110 • ACR Convergence 2025
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Yuka Nakao¹, Astha Patel¹, Bahram Razani², Steven yu¹, Steven Lazarevsky², Marlys Fassett² and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF Department of Dermatology, San Francisco, CA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
Abstract Number: 0080 • ACR Convergence 2025
The Role of DICAM in Modulating Macrophage Differentiation and Inflammatory Responses via αvβ3 Integrin Signaling in Rheumatoid Arthritis
Hanna Lee¹, Youn-Kwan Jung², Sang-il Lee³, Yun-Hong Cheon⁴ and Hyunjin Lim⁴, ¹Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Changwon, Changwon-si, Kyongsang-namdo, Republic of Korea, ²Institute of Medical Science, Gyeongsang National University, Jinju, Jinju, Kyongsang-namdo, Republic of Korea, ³Department of Internal Medicine and Institute of Medical Science, College of Medicine, Gyeongsang National University and Hospital, Jinju, Republic of Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Jinju, Kyongsang-namdo, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation, cartilage destruction, and bone erosion. Among the various immune cells involved…
Abstract Number: 0079 • ACR Convergence 2025
Association of Protein Arginine Deiminase 4 with the Myosin-9 Motor Complex
Fatemeh Neela Moadab, Farheen Shaikh, Xiaoxing Wang, cecilia mustelin, Ethan Le, Rayan Najjar, Jie An, Alison Bays and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Genetic association data, immunohistochemistry, and functional experiments implicate protein arginine deiminase 4 (PAD4) in the pathogenesis of rheumatoid arthritis (RA). This disease is characterized…
Abstract Number: 0033 • ACR Convergence 2025
Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
Lauren Vanderlinden¹, Jun Inamo², Jennifer Seifert³, V. Michael Holers⁴, Joel Guthridge⁵, Kevin Deane⁶ and Fan Zhang⁷, ¹University of Colorado Anschutz Medical Campus, Monument, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁷The University of Colorado, Aurora, CO
Background/Purpose: Human leukocyte antigen (HLA) class II genes play a central role in antigen presentation and immune modulation. The shared epitope (SE) region within HLA-DRB1…
Abstract Number: 0024 • ACR Convergence 2025
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Daniel Panyard¹, Daniel Li², Pik Fang Kho², Rodrigo Guarischi-Sousa³, Jiayan Zhou², Austin Hilliard⁴, Christie Bartels⁵, Philip Tsao² and Themistocles Assimes², ¹Stanford University, Sunnyvale, CA, ²Stanford University, Palo Alto, CA, ³Palo Alto Veterans Institute for Research, Palo Alto, CA, ⁴VA Palo Alto Health Care, Palo Alto, CA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].